
Tango Therapeutics, Inc.
- Jurisdiction
United States - ISIN
US87583X1090 (TNGX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Read full profile
Fundamentals
- Net revenue
€20.72M - Gross margin
97.4% - EBIT
-€134.16M - EBIT margin
-647.3% - Net income
-€124.16M - Net margin
-599.1%
Statement period: - (published )
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
Name | Title | Transaction Date | Shares | Price | Value |
---|---|---|---|---|---|
TRV GP IV, LLC | N/A |
|
|
|
|
TRV GP IV, LLC | N/A |
|
|
|
|
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Buy |